FDA names volixibat, for itching due to PBC, a breakthrough therapy
The U.S. Food and Drug Administration (FDA) has designated Mirum Pharmaceuticals’ oral candidate volixibat a breakthrough therapy for the treatment of itching, or…
Fewer than half of reproductive-aged women with opioid use disorder in the U.S. undergo hepatitis C testing, with Black and Asian women less likely than their white counterparts to be screened for the viral infection, according to a new study. Among women in the study who did test positive…
Read MoreThe U.S. Food and Drug Administration (FDA) has designated Mirum Pharmaceuticals’ oral candidate volixibat a breakthrough therapy for the treatment of itching, or…
A new ABCB11 gene mutation was the likely cause of progressive familial intrahepatic cholestasis type 2 (PFIC2) in a boy who was also born with…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to survodutide, an experimental injectable therapy by Boehringer Ingelheim for metabolic dysfunction-associated steatohepatitis…